MIR573

Summary

MIR573 (microRNA 573, HGNC:32829) is a microRNA gene on chromosome 4p15.2.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 693158 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:32829
Approved symbol	MIR573
Name	microRNA 573
Location	4p15.2
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-573
Ensembl gene	ENSG00000207697
Ensembl biotype	miRNA
Entrez	693158
RNAcentral	URS00006A04D9 — miRNA, 99 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000384964

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000384964 — 1 exons

Exon	Start	End
ENSE00001499971	24520192	24520290

Expression profiles

Bgee: expression breadth ubiquitous, 117 present calls, max score 94.77.

Top tissues by expression

117 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
calcaneal tendon	UBERON:0003701	94.77	gold quality
corpus callosum	UBERON:0002336	94.34	gold quality
right hemisphere of cerebellum	UBERON:0014890	93.13	gold quality
left uterine tube	UBERON:0001303	92.97	gold quality
cerebellar hemisphere	UBERON:0002245	92.74	gold quality
endometrium	UBERON:0001295	92.57	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	91.63	gold quality
right ovary	UBERON:0002118	91.29	gold quality
monocyte	CL:0000576	91.24	gold quality
body of uterus	UBERON:0009853	91.06	gold quality
right lung	UBERON:0002167	90.85	gold quality
endocervix	UBERON:0000458	90.74	gold quality
right uterine tube	UBERON:0001302	90.55	gold quality
leukocyte	CL:0000738	90.39	gold quality
adrenal tissue	UBERON:0018303	89.58	gold quality
tibial nerve	UBERON:0001323	89.09	gold quality
fundus of stomach	UBERON:0001160	88.94	gold quality
myometrium	UBERON:0001296	88.86	gold quality
ovary	UBERON:0000992	88.81	gold quality
ectocervix	UBERON:0012249	88.56	gold quality
left ovary	UBERON:0002119	88.37	gold quality
small intestine Peyer’s patch	UBERON:0003454	88.36	gold quality
transverse colon	UBERON:0001157	88.02	gold quality
tibial artery	UBERON:0007610	88.00	gold quality
stomach	UBERON:0000945	87.96	gold quality
popliteal artery	UBERON:0002250	87.95	gold quality
skin of abdomen	UBERON:0001416	87.94	gold quality
bone marrow	UBERON:0002371	87.89	gold quality
zone of skin	UBERON:0000014	87.74	gold quality
small intestine	UBERON:0002108	87.69	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.23

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 15)

• expression levels of miR-573 were lower in melanoma tissues and cell lines compared to normal skin tissues. miR-573 upregulation inhibited melanoma cell proliferation and invasion. (PMID:23670160)
• ADAR1 regulates the expression of ARHGAP26 through A-to-I RNA editing by disrupting the binding of miR-30b-3p and miR-573 within the 3’ UTR of ARHGAP26. (PMID:24067935)
• Our data highlight the role of miR-578 and miR-573 in controlling BRCA 1/2-related angiogenesis in a series of familial breast cancers (PMID:25333258)
• Restoration of TSPAN1 rescued the effects of miR-573 overexpression. Therefore, our findings suggest that the miR-573/TSPAN1 axis is important in the control of gastric carcinogenesis (PMID:26054975)
• This study points toward the protective roles of miR-573 in the pathological process of rheumatoid arthritis. (PMID:26166764)
• hsa-miR-573 promoted tumor growth by inhibition of hepatocyte apoptosis and this pro-tumor effect might be mediated through Bcl2A1 in an apoM-dependent manner. (PMID:26201458)
• Findings demonstrate a novel mechanism by which miR-573 modulates EMT and metastasis of PCa cells. (PMID:26451614)
• lncRNA TTN-AS1 was involved in the progression of CC cells by regulation of miR-573-E2F3 axis (PMID:30135013)
• findings suggested that FLVCR1-AS1/miR-573/E2F3 axis was an important signaling pathway in mediating tumorigenesis and progression of NSCLC (PMID:30309647)
• These results suggest that overexpression of miR-573 inhibited nucleus pulposus cell apoptosis by down-regulating Bax. (PMID:30936926)
• Long noncoding RNA SNHG1 promotes breast cancer progression by regulation of LMO4. (PMID:32323846)
• miR-573 suppresses pancreatic cancer cell proliferation, migration, and invasion through targeting TSPAN1. (PMID:33320287)
• Mir-573 regulates cell proliferation and apoptosis by targeting Bax in human degenerative disc cells following hyperbaric oxygen treatment. (PMID:33413477)
• Circular RNA circ_0079593 enhances malignant melanoma progression by the regulation of the miR-573/ABHD2 axis. (PMID:33648800)
• MicroRNA 573 Rescues Endothelial Dysfunction during Dengue Virus Infection under PPARgamma Regulation. (PMID:35108097)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.